Why it Matters
Secretome Therapeutics’ decision to enter federal lobbying marks its first formal advocacy effort. The biotech company hired experienced healthcare lobbyists at a crucial time for neonatal stem cell research. Congress is actively reauthorizing major research programs and debating new regulatory frameworks, positioning Secretome to influence key decisions affecting its neonatal cardiac progenitor cell therapies.
By the Numbers
Secretome retained Thorn Run Partners on July 1, 2025, filing its first lobbying registration July 18. The company has no previous lobbying history on record. Two lobbyists will handle the account: Thayer Surette Roberts and Andrew Marc Rosenberg. Roberts has lobbied for the Biosimilars Forum and Modern Medicaid Alliance. Rosenberg represents major clients including Novartis Corp., GlaxoSmithKline LLC, and the Medical Device Manufacturers Association.
Broader Context
Congress is wrestling with America’s declining biomedical research leadership as China increases investment. Lawmakers expressed concern over proposed NIH funding cuts during recent Senate hearings. The FDA faces workforce reductions that could slow new medical product reviews. Biotechnology priorities are getting increased attention as Chinese firms make significant gains in the sector.
The Agenda
Secretome’s lobbying focuses on “education related to neonatal stem cell research” under health issues. The company develops cell-free therapies from neonatal cardiac progenitor cells for cardiovascular diseases. Their approach avoids transplanting whole cells into patients, reducing complexity and risks. One therapy has received FDA Fast Track Designation for heart failure treatment.
Competitive Landscape
Secretome joins an active stem cell lobbying ecosystem. jCyte Inc. recently registered to lobby on cell therapy development. Vertex Pharmaceuticals lobbies on cell and gene therapy access. SK Americas Inc. spent $1.64 million in one quarter on cell and gene therapy advocacy. Professional groups like the American Society of Gene & Cell Therapy and National Stem Cell Foundation Inc. actively lobby for research funding.
Between The Lines
Key legislation is moving through Congress affecting Secretome’s interests. The H.R.5160 – Stem Cell Therapeutic and Research Reauthorization Act of 2025 has bipartisan support from lawmakers like Rep. Bilirakis and Rep. Tenney. The H.R.1082 – Shandra Eisenga Human Cell and Tissue Product Safety Act passed the House unanimously, celebrated by Representatives Moolenaar and Dingell. Ethics remain contentious, with Rep. Chris Smith pushing to end embryonic stem cell funding while Sen. Cantwell defends all stem cell research. Recent hearings addressed biomedical research funding and biotechnology priorities.
The Bottom Line
Secretome enters lobbying during active congressional engagement on stem cell policy. Their neonatal cell focus aligns with ethical preferences favoring non-embryonic sources. The company’s timing capitalizes on bipartisan support for research funding and regulatory modernization. Success will depend on effectively educating policymakers about their specific approach.
All data used in this article came from Legis1. Request a demo to learn more!
Spot something wrong? Report an issue with this article